Connection

LAWRENCE DONEHOWER to Heterozygote

This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Heterozygote.
Connection Strength

0.567
  1. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ. 1999 Apr; 10(4):213-22.
    View in: PubMed
    Score: 0.136
  2. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998 Aug 17; 17(16):4657-67.
    View in: PubMed
    Score: 0.131
  3. Functional analysis of tumor suppressor genes in mice. Methods Mol Biol. 2003; 223:283-314.
    View in: PubMed
    Score: 0.044
  4. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol. 2001; 29 Suppl:24-9.
    View in: PubMed
    Score: 0.039
  5. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995 Sep; 14(1):16-22.
    View in: PubMed
    Score: 0.027
  6. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet. 1995 Mar; 9(3):305-11.
    View in: PubMed
    Score: 0.026
  7. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 1995 Mar 01; 55(5):1146-51.
    View in: PubMed
    Score: 0.026
  8. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993 Nov; 5(3):225-9.
    View in: PubMed
    Score: 0.023
  9. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19; 356(6366):215-21.
    View in: PubMed
    Score: 0.021
  10. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat. 2011 Nov; 130(2):399-408.
    View in: PubMed
    Score: 0.019
  11. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res. 2004 Aug 01; 64(15):5140-7.
    View in: PubMed
    Score: 0.012
  12. Visual genotyping of a coat color tagged p53 mutant mouse line. Cancer Biol Ther. 2002 Jul-Aug; 1(4):433-5.
    View in: PubMed
    Score: 0.011
  13. p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis. 2000 Oct; 21(10):1891-7.
    View in: PubMed
    Score: 0.009
  14. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000 Jun 15; 14(12):1448-59.
    View in: PubMed
    Score: 0.009
  15. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15608-12.
    View in: PubMed
    Score: 0.008
  16. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):14106-11.
    View in: PubMed
    Score: 0.007
  17. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene. 1995 Jul 06; 11(1):181-90.
    View in: PubMed
    Score: 0.007
  18. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene. 1995 Apr 06; 10(7):1269-74.
    View in: PubMed
    Score: 0.006
  19. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell. 1993 Sep 10; 74(5):813-22.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.